Скачать или смотреть Analytical performance of TruSight™ Oncology 500 ctDNA v2

Presented By: Jennifer S. Lococo, PhD, Maria Jarama Ruiz, B.S., M.S. & Biswajit Das, Ph.D.

Speaker Biography: Jennifer S. LoCoco, PhD is a Director of Assay Development at Illumina. She earned her Bachelor of Sciences degree in Biology from the University of Utah and a PhD in Molecular Biology at The University of California, San Diego. Following postdoctoral work on transcriptional control of ciliogenesis at the Salk Institute for Biological Sciences she started her career in assay development with a focus on genetic testing. She and her team currently work to design and optimize library preparation methods to enrich for oncology relevant variants in various biopsy types (FFPE, cfDNA) for further interrogation using next generation sequencing.

Webinar: Analytical performance of TruSight™ Oncology 500 ctDNA v2

Webinar Abstract: Next-generation sequencing (NGS) based liquid biopsy is emerging as standard of care in oncology for comprehensive genomic profiling (CGP) of solid tumors. In this presentation we will showcase the analytical performance of TruSight™ Oncology 500 ctDNA version 2 (TSO 500 ctDNA v2, Illumina, San Diego, CA; Research Use Only), an NGS-based assay that utilizes the same gene panel as TSO 500 ctDNA. Its improved workflow reduces cfDNA input requirements, total turn-around time and hands-on time while still delivering all key biomarker data available from the TSO 500 gene panel.

Labroots on Social:
Facebook:   / labrootsinc  
Twitter:   / labroots  
LinkedIn:   / labroots  
Instagram:   / labrootsinc  
Pinterest:   / labroots  
SnapChat: labroots_inc